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OBJECTIVES This study aimed to characterize the difference between renin angiotensin system (RAS)-
dependent and RAS-independent hypertrophy and their differential contribution to the
transition to heart failure.
BACKGROUND Hypertensive left ventricular (LV) hypertrophy develops with RAS activation in the heart;
however, LV hypertrophy develops even without RAS activation.
METHODS Left ventricular geometry and function were assessed in Dahl salt-sensitive rats placed on an
8% NaCl diet from seven weeks old (hypertensive rats) and in those placed on an 0.3% NaCl
diet (control rats, n 5 8). The hypertensive rats were randomized to no treatment (n 5 8) or
treatment with the angiotensin type 1 receptor (AT1R) antagonist candesartan (1 mg/kg per
day, n 5 10) after the baseline echocardiography study.
RESULTS From 7 to 13 weeks, AT1R blockade at a subdepressor dose did not restrain the development
of LV hypertrophy but prevented narrowing of LV diastolic dimension, leading to the
normalization of abnormally decreased end-systolic wall stress in the untreated rats.
Progressive development of LV hypertrophy in spite of lower than normal end-systolic wall
stress (excessive hypertrophy) after 13 weeks was suppressed by the AT1R blockade. Elevation
of LV end-diastolic pressure and prolongation of Tau were associated with histological
evidence of myocyte hypertrophy and massive interstitial fibrosis in the untreated rats, and
none of these was evident in the treated rats.
CONCLUSIONS Renin-angiotensin system activation and AT1R signaling may be dispensable for the
development of early adaptive LV hypertrophy and closely linked to the transition to heart
failure. (J Am Coll Cardiol 2001;37:293–9) © 2001 by the American College of Cardiology
Ventricular hypertrophy as a physiological response to
chronic pressure overload initially normalizes wall stress but
may eventually result in a deterioration of contractile func-
tion, alter left ventricular (LV) geometry or decrease cham-
ber compliance. Any of these changes may contribute to the
development of heart failure; however, the mechanism
accounting for the transition from compensatory hypertro-
phy to heart failure is not well understood. Evidence from
many experimental studies supports the idea that local
activation of the renin angiotensin system (RAS) is closely
related to the development of cardiac hypertrophy. The
expression of angiotensin-converting enzyme (ACE) and
angiotensin type-1 receptor (AT1R) messenger RNA
(mRNA) is induced in the hypertrophied rat heart (1,2).
Mechanical stress stimulates the secretion of angiotensin
(AT) II from myocytes, and AT II, in turn, induces
cardiomyocyte hypertrophy through AT1R (3,4). This evi-
dence supports the idea that RAS plays an important role in
the development of pressure overloaded hypertrophy. In
fact, pharmacological blockade of RAS with ACE inhibi-
tion regresses LV hypertrophy in patients as well as in
animal models (5–7). In contrast, there are several pieces of
evidence that the activation of RAS may be dispensable for
LV hypertrophy. Administration of the AT1R antagonist
did not completely prevent stress-induced hypertrophy in
rats with persistent systolic pressure overload due to ascend-
ing aortic stenosis (8), and cardiac hypertrophy was induced
by pressure overloading in AT1R knockout mice (9,10).
Both of these studies indicate that activation of RAS is not
essential for the development of cardiac hypertrophy. Thus,
the role of RAS in the development of cardiac hypertrophy
is still controversial.
The aim of this study was to characterize the difference
between RAS-dependent and RAS-independent hypertro-
phy in hypertensive rats and to clarify their differential
contribution to the transition from compensatory to failing
stage. Specifically, we studied the effect of AT1R antagonist
administration on the development of hypertrophy and,
hence, heart failure in Dahl salt-sensitive rats in which
development of hypertension is followed by compensatory
LV hypertrophy at 13 weeks old and, in turn, by the
transition to heart failure at 19 weeks old.
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METHODS
This study conforms to the guiding principles of the Osaka
University School of Medicine with regard to animal care
and to the position of the American Heart Association on
research animal use. Our study consisted of two experimen-
tal protocols.
Protocol 1: 19 weeks end-point study. Laboratory chow
containing 0.3% NaCl was continuously fed to the male
Dahl-Iwai salt-sensitive (Dahl S) rats (DIS/Eis, Eisai,
Tokyo, Japan), and they were defined as control rats (n 5
8). Laboratory chow containing 0.3% NaCl was fed to
weanling Dahl S rats until their diet was switched at seven
weeks old to laboratory chow containing 8% NaCl for the
other rats (n 5 18). We randomly selected 10 out of 18 rats,
and these rats were given candesartan cilextil (1 mg/kg per
day, courtesy of Takeda Chemical Industries Ltd: group
CAND[1]). The dose of candesartan was determined
according to the data in a preliminary study. The other eight
rats were given placebo (group CAND[2]). The diet and
tap water were given ad libitum throughout the experiment.
Systolic blood pressure and heart rate were measured every
two to five weeks with a tail-cuff system (BP-98A, Softron,
Tokyo, Japan).
Protocol 2: 13 weeks end-point study. Pathological and
neurohumoral conditions in the stage of compensatory
hypertrophy were studied as protocol 2 using six control
rats, seven untreated rats and seven rats treated with
candesartan. In these rats post mortem, the ratio of LV mass
to body weight (LVMI) and LV mRNA levels were
measured at 13 weeks. The production of the model for this
protocol is the same as that described in protocol 1.
Doppler echocardiography and hemodynamic studies.
Transthoracic echocardiography Doppler studies were per-
formed at 7 (just before starting 8% NaCl diet), 13, 15, 17
and 19 weeks to determine LV mass, relative wall thickness,
systolic wall stress, endocardial and midwall fractional
shortening, peak early diastolic filling velocity (E velocity)
and peak filling velocity at atrial contraction (A velocity) in
a fashion previously described (11,12). Hemodynamic stud-
ies were performed at 19 weeks. Soon after Doppler
echocardiography studies, LV catheterization was per-
formed for the determination of time constant (Tau) and
end-diastolic pressure as previously described (11).
Pathological studies. After the hemodynamic studies, ad-
equate anesthesia was achieved, and lung weight and LV
mass were measured as previously described (11). Left
ventricular myocardium was sampled for measurement of
hydroxyproline, histological examination and mRNA quan-
tification. Hydroxyproline content was measured as previ-
ously described (13). The rest of the left ventricle was fixed
with a phosphate-buffered 10% formalin solution for a
week. The specimens were embedded in paraffin, and 2-mm
thick transverse sections of the organs were stained with
hematoxylin and eosin for routine histological examination
and with Azan Mallory stain to evaluate the degree of
fibrosis. Myocyte diameter was measured from myocytes
that were cut transversely and had both a visible nucleus and
an unbroken cellular membrane. At least 100 cells were
counted per heart, and the average was used for analysis.
The percent area of fibrosis in the left ventricle at the
papillary muscle level in the slices stained with Azan
Mallory stain at 3100 magnification was determined by
previously described computer analysis method (11).
Quantitative reverse-transcriptase polymerase chain re-
action analysis. Quantitative reverse-transcriptase poly-
merase chain reaction analysis was performed using Prism
7700 Sequence Detector (The Perkin-Elmer Corporation,
Foster, California) as previously described (13,14). We
measured mRNAs of ACE, AT1a receptor, prepro endo-
thelin (ET)-1, endothelin-converting enzyme (ECE), ET
type A receptor, ET type B receptor and glyceraldehyde-3-
phosphate-dehydrogenase. These sequences of all oligonu-
cleotides used as forward primers, reverse primers and
detection probes were shown in the previous paper (13). To
correct the efficiency of cyclic DNA synthesis, the amounts
of mRNAs were divided by the amounts of glyceraldehyde-
3-phosphate-dehydrogenase mRNA.
Statistical analysis. Results are expressed as mean values 6
SEM. All statistical analyses were performed using a com-
mercially available statistical software (STATVIEW version
4.54, Abacus Concepatients, Berkeley, California). The
serial data were analyzed by analysis of variance for repeated
measurements. Differences at specific stages among groups
were assessed using one-factor analyses of variance and
Scheffe’s test. A p value of ,0.05 was considered statistically
significant.
RESULTS
Hemodynamics and heart failure. Aortic pressure was
slightly, although statistically significant, decreased in
CAND(1) rats at 13 weeks compared with CAND(2) rats
(Table 1). The ratio of lung weight to body weight in-
creased, and LV end-diastolic pressure was elevated in most
of CAND(2) rats reflecting congestive heart failure at 19
weeks (Table 2). Chronic administration of AT1R antago-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AT 5 angiotensin
AT1 R 5 angiotensin II type-1 receptor
CAND(1) 5 experimental group receiving candesartan
CAND(2) 5 experimental group receiving placebo
ECE 5 endothelin-converting enzyme
ET 5 endothelin
LV 5 left ventricular
LVMI 5 the ratio of left ventricular mass to body
weight
mRNA 5 messenger RNA
RAS 5 renin angiotensin system
Tau 5 time constant of left ventricular isovolumic
pressure fall
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nist prevented the increases. Left ventricular systolic func-
tion assessed with midwall fractional shortening was not
different among the control, CAND(2) and CAND(1)
rats throughout the experiment (Table 1). End-systolic
stress increased up to 13 weeks and gradually decreased
thereafter in the control rats, and its initial increase was
considered an aging process (Table 1). End-systolic stress
was significantly lower in CAND(2) rats at 13 weeks
compared with the control rats. It gradually increased after
13 weeks and was equal to the level of the control rats at 19
weeks. In CAND(1) rats, there was no decrease in end-
systolic stress compared with the control rats at 13 through
19 weeks.
LV geometrical change. Echocardiography determined
posterior wall thickness at end-diastole and LVMI in-
creased both in CAND(2) and CAND(1) rats at 13
weeks, and there was no significant difference in LVMI
between the two groups (Table 1, Fig. 1). Left ventricle
end-diastolic dimension was smaller in CAND(2) rats than
it was in the control rats at 13 weeks, and, consequently,
relative wall thickness was increased in CAND(2) rats.
Angiotensin II type-1 receptor antagonist administration
attenuated the increase in relative wall thickness. After 13
weeks CAND(2) rats showed a progressive increase in wall
thickness and LVMI, and these changes were attenuated by
AT1R antagonist administration (Table 1, Fig. 1). The data
of postmortem LVMI confirmed the echocardiography
results (Fig. 2).
Histological study. Myocyte diameter was increased in
CAND(2) rats at 19 weeks, and the increase was reduced
by AT1R antagonist administration (Table 2). CAND(2)
rats showed perivascular and interstitial fibrosis at 19 weeks
(Fig. 3), particularly in the subendocardial portion. Massive
fibrosis was not observed in CAND(1) rats. The findings
were confirmed by the data of percent area of fibrosis and
hydroxyproline content (Table 2).
LV mRNA levels. At 13 weeks LV ACE mRNA levels
were slightly, but significantly, higher in the CAND(2)
Table 1. Changes in Echocardiographic Parameters in the Control Rats and Rats of Group CAND(2) and CAND(1)
SBP
(mm Hg)
PWd
(mm)
LVDd
(mm)
FS
(%)
MFS
(%)
RWT
(%)
LVMI
(mg/g)
ESS
(103 dynes/cm2) E/A
Control (n 5 8)
7 weeks 121 6 3 1.1 6 0.1 7.3 6 0.1 41 6 1 21 6 1 31 6 1 2.7 6 0.1 56 6 4 1.6 6 0.1
13 weeks 144 6 3 1.3 6 0.1 8.8 6 0.1 30 6 2 16 6 1 29 6 1 2.2 6 0.1 107 6 9 2.4 6 0.3
19 weeks 146 6 3 1.5 6 0.1 8.7 6 0.2 31 6 1 14 6 1 36 6 2 2.2 6 0.1 83 6 5 2.6 6 0.4
CAND(2) (n 5 8)
7 weeks 126 6 3 1.1 6 0.1 7.3 6 0.1 42 6 1 22 6 1 30 6 1 2.6 6 0.1 52 6 5 1.6 6 0.1
13 weeks 232 6 2† 2.2 6 0.1† 7.3 6 0.3† 41 6 2† 14 6 1 61 6 4† 3.3 6 0.1† 52 6 9† 1.1 6 0.1†
19 weeks 231 6 2† 2.5 6 0.2† 8.4 6 0.2 36 6 1 15 6 1 61 6 5‡ 4.4 6 0.2† 72 6 6 3.7 6 0.7
CAND(1) (n 5 10)
7 weeks 122 6 2 1.1 6 0.1 7.4 6 0.1 39 6 1 22 6 1 30 6 1 2.7 6 0.1 63 6 3 1.7 6 0.1
13 weeks 218 6 4†‡ 1.9 6 0.1†§ 8.6 6 0.2§ 29 6 1§ 13 6 1 44 6 1†‡ 3.1 6 0.1† 120 6 11§ 0.8 6 0.1†
19 weeks 220 6 4† 2.0 6 0.1*‡ 8.7 6 0.1 35 6 1 15 6 1 45 6 2‡ 3.2 6 0.3†§ 94 6 7 1.4 6 0.4§
P value by repeated
measurements ANOVA
Main effect
Group ,0.0001 ,0.0001 ,0.0001 0.0012 0.70 ,0.0001 ,0.0001 0.0002 0.0004
Time course ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001
Interaction ,0.0001 ,0.0001 0.0006 0.001 0.27 ,0.0001 ,0.0001 0.0002 ,0.0001
Values are expressed as mean 6 SEM. *p , 0.05; †p , 0.01 versus control rats; ‡p , 0.05; §p , 0.01 vs. CAND(2) of same age rats.
ANOVA 5 analysis of variance; CAND(1) 5 group treated with candesartan; CAND(2) 5 placebo group; E/A ratio 5 the ratio of peak filling velocity at atrial contraction
to peak early diastolic filling velocity; ESS 5 end-systolic wall stress; FS 5 fractional shortening of LV inner diameter; LV 5 left ventricular; LVDd 5 LV end-diastolic
dimension; LVMI 5 ratio of LV mass to body weight; MFS 5 midwall fractional shortening of LV inner diameter; PWd 5 LV posterior wall thickness at end-diastole; SBP 5
systolic blood pressure.
Table 2. Results of Hemodynamics and Pathology at 19 Weeks
Control CAND(2) CAND(1)
p Value by
ANOVA
LV systolic pressure (mm Hg) 149 6 7 196 6 4† 218 6 9† ,0.0001
Lung/wt (mg/g) 3.8 6 0.1 7.5 6 1.3† 4.0 6 0.1‡ 0.0023
LVEDP (mm Hg) 9 6 1 19 6 2† 7 6 2§ ,0.0001
Tau (ms) 23 6 2 29 6 1* 24 6 1‡ 0.0082
Myocyte diameter (mm) 14.0 6 0.3 17.4 6 0.4† 14.9 6 0.3§ ,0.0001
Area of fibrosis (%) 2.0 6 0.4 7.5 6 1.3† 3.7 6 0.6§ 0.0001
Pro-OH (mmol/g) 2.4 6 0.2 4.1 6 0.2† 2.8 6 0.5‡ 0.0003
Values are expressed as mean 6 SEM. *p , 0.05; †p , 0.01 versus control group; ‡p , 0.05; §p , 0.01 versus CAND(2)
group.
ANOVA 5 analysis of variance; CAND(1) 5 group treated with candesartan; CAND(2) 5 placebo group; lung/wt 5 ratio
of lung weight to body weight; LV 5 left ventricular; LVEDP 5 LV end-diastolic pressure; Pro-OH 5 hydroxyproline
concentration; Tau 5 time constant of left ventricular isovolumic pressure fall.
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group than they were in the control group and were similar
between CAND(2) and CAND(1) rats (p , 0.0001). At
19 weeks LV ACE mRNA level was increased in
CAND(2) compared with control and was significantly
attenuated in CAND(1) (p , 0.0001). Left ventricular
AT1a mRNA level was not different between any of the
three groups at 13 or 19 weeks (p 5 0.27 and 0.17,
respectively) (Fig. 4).
The prepro ET-1 mRNA level was not different among
the three groups at 13 weeks (p 5 0.044). At 19 weeks
prepro ET-1 RNA levels were significantly elevated in
CAND(2) (p , 0.0001). This elevation was significantly
attenuated in the CAND(1) group. Nor were ECE, ET
type A and ET type B receptor mRNA levels different
among the three groups at 13 weeks (p 5 0.17, 0.11 and
0.70, respectively). At 19 weeks these mRNA levels were
increased in CAND(2) rats, and the induction was atten-
uated by AT1R antagonist administration (p 5 0.0099,
0.0007 and ,0.0001, respectively) (Fig. 5).
AT1R antagonist versus ACE inhibitor. Renin-
angiotensin system activation may be blocked at different
levels and result in different outcomes (15). We studied an
additional 15 rats in our model treated with enalapril (5
mg/kg/day) from 8 weeks to 19 weeks. Effects of ACE
inhibition were comparable with those of candesartan in this
study (Table 3).
DISCUSSION
In this study, administration of the AT1R antagonist,
candesartan, did not suppress initial development of LV
hypertrophy although it attenuated the geometrical changes
in LV chamber dimensions at 13 weeks. However, further
development of hypertrophy and interstitial fibrosis was
suppressed after 13 weeks by candesartan, which likely
contributed to the prevention of transition to heart failure in
hypertensive rats. These results indicate that RAS signaling
through AT1R may be dispensable for initial hypertension-
induced adaptive LV hypertrophy in this model. In contrast,
AT1R signaling appears to be involved in the maintenance
of LV hypertrophy and closely linked with the transition to
heart failure.
RAS-dependent versus RAS-independent hypertrophy.
Left ventricular hypertrophy developed from 7 to 13 weeks
both in CAND(2) and CAND(1) rats to the same degree,
indicating that LV hypertrophy at this stage occurs inde-
pendent of RAS activation. This result is supported by the
data of recent experimental studies. Cardiac hypertrophy
was induced by pressure overload in AT1a knockout mice
(10), and extracellular signal-regulated protein kinases were
strongly activated in myocytes of AT1a knockout mice (16).
Left ventricular hypertrophy was suppressed by the admin-
istration of tyrosine kinase inhibitor and selective inhibitors
of epidermal growth factor receptor in AT1a knockout mice
(16). Activation of signal-regulated protein kinase was
observed also in wild type myocytes, and mechanical stretch
may likely evoke hypertrophic responses in cardiac myocytes
lacking in the AT1 signaling pathway, possibly through
tyrosine kinase activation. Another in vitro study showed
that LV c-fos and c-myc mRNA levels and the rate of
phenylalanine incorporation into cardiac proteins were in-
creased in isolated perfused adult rat hearts subjected to
increased systolic load and that AT1R blockade with losar-
tan did not prevent these hypertrophic responses (17). Thus,
there is considerable evidence indicating independence of
development of LV hypertrophy from RAS activation.
However, previous studies failed to characterize the differ-
ence between RAS-dependent and RAS-independent LV
hypertrophies.
Characteristics of RAS-dependent hypertrophy. First,
RAS activation may be involved in concentric geometrical
LV chamber remodeling at 13 weeks old. Relative wall
thickness was greater in CAND(2) rats than it was in the
control rats, and the increase was attenuated by chronic
AT1R antagonist administration without any effect on
LVMI. The difference in chamber size accounts for subnor-
mal systolic wall stress in CAND(2) rats and for normal
systolic wall stress in CAND(1) rats. The significant
Figure 2. Postmortem LVMI at 13 and 19 weeks in control, CAND(2)
and CAND(1) rats. **p , 0.01 vs. control group; ††p , 0.01 vs.
CAND(2) group. p value of analysis of variance main effects: 13 weeks:
,0.0001; 19 weeks: ,0.0001. Values are means 6 SEM. LVMI 5 left
ventricular mass index.
Figure 1. Serial changes in LV mass index in control, CAND(2) and
CAND(1) rats. p value of analysis of variance main effects: group,
,0.0001; time course, ,0.0001. p value of analysis of variance interaction,
,0.0001. **p , 0.01 versus control group; †† p , 0.01 versus CAND(2)
group at same time point. Values are means 6 SEM. LV 5 left ventricular.
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elevation of ACE mRNA at 13 weeks in CAND(2) rats
may support the idea that RAS activation is already,
although partially, involved in compensatory hypertrophy in
CAND(2) rats. Sugishita et al. (18) showed in hypertensive
patients that regression of LV hypertrophy was not achieved
with the administration of the antihypertensives, such as Ca
channel antagonist and diuretics, in the condition of sub-
normal systolic wall stress. They speculate the involvement
of neurohumoral factors in LV geometrical changes in such
patients. Our data may explain the failure to obtain regres-
sion of LV hypertrophy with the use of Ca channel
antagonist or diuretics in their patients. The RAS may have
been abnormally activated in their patients. Future studies
are needed both from the molecular and clinical viewpoints
to disclose the relation between RAS activation and geo-
metrical remodeling.
Second, we showed that RAS activation and signaling
through the AT1R is associated with excessive hypertrophy
and a transition to heart failure. After 13 weeks, LVMI in
CAND(2) rats progressively increased in spite of lower
than or equal to normal systolic wall stress up to 19 weeks.
Although AT1R antagonist administration did not affect
LVMI at 13 weeks old, it suppressed the progressive
development of additional LV hypertrophy thereafter.
These results suggest that LV hypertrophy in CAND(2)
rats after 13 weeks may be related to RAS activation. This
idea is supported by the data of ACE mRNA levels, which
were elevated in CAND(2) rats and were reduced by AT1R
antagonist administration at 19 weeks. A recent in vitro
study showed that AT1R antagonist, losartan, inhibited AT
II-induced upregulation of ACE mRNA in neonatal cardiac
myocytes (19).
In addition, excessive hypertrophy was accompanied by
interstitial fibrosis in this study. We previously reported that
interstitial fibrosis also occurred after 13 weeks in the
CAND(2) rats (13). These structural changes may well
contribute to LV dysfunction, particularly to diastolic dys-
function, because the effects of fibrosis on LV diastolic
properties are well known (20,21). In fact, although midwall
fractional shortening was not different among the three
groups, LV diastolic filling pattern was characterized by
high E and low A waves (restrictive pattern) at 19 weeks in
the CAND(2) rats, suggesting the presence of advanced
LV diastolic dysfunction without severe systolic dysfunction
(22). This interpretation was supported by the abnormal
values of LV high fidelity pressure-derived parameters, that
is, LV end-diastolic pressure and a reference of LV relax-
ation, Tau. Thus, both excessive hypertrophy and massive
Figure 3. Photomicrographs of Azan Mallory staining of left ventricle in a CAND(2) rat (left panel) and a CAND(1) rat (right panel) (340). Interstitial
and perivascular fibrosis is evident only in CAND(2) rats.
Figure 4. The mRNA levels of ACE, AT1a receptor at 13 and 19 weeks
old. Each mRNA level was corrected for an mRNA level of
glyceraldehyde-3-phosphate-dehydrogenase and was then normalized to a
mean value of age-matched control group, respectively. **p , 0.01 versus
control group; ††p , 0.01 versus CAND(2) group. Values are means 6
SEM. Hatched bar5 control; solid bar5 CAND(2); open bar5
CAND(1). ACE 5 angiotensin-converting enzyme; mRNA 5 messen-
ger RNA.
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interstitial fibrosis are characteristics of RAS-dependent
hypertrophy, which is likely to contribute to the progression
of LV diastolic dysfunction and, hence, to the transition to
heart failure, particularly diastolic heart failure.
Interaction with ET pathway in RAS-dependent hyper-
trophy. Renin-angiotensin system activation has been con-
sidered to interact with other neurohumoral factors, partic-
ularly ET-1. Endothelin-1 as well as AT II are G-protein-
coupled receptor agonists that induce hypertrophy and
interstitial fibrosis (23,24). In in vitro studies, AT II
stimulated cultured bovine endothelial cells to release ET-1
to activate the expression of prepro endothelin-1 mRNA
(25). Further, endogenous ET-1, locally generated and
secreted by cardiomyocytes, facilitates AT II-induced car-
diac hypertrophy via autocrine/paracrine fashion (26). Pre-
pro endothelin-1 mRNA and ECE-1 mRNA levels were
enhanced with upregulation of ET type A and ET type B
receptors mRNAs in CAND(2) rats at 19 weeks old.
Chronic AT1R blockade modulated the expression of pre-
pro endothelin-1 mRNA and attenuated the upregulation
of ET receptors at failing stage. These results suggest that
RAS activation and signaling through the AT1R contribute
to the development of heart failure at least partially via the
activation of the ET pathway in vivo. Further studies using
ET receptor blocker may help in understanding the inter-
action between the RAS and the ET pathway in vivo in the
pathology of heart failure because this is only a model of
hypertrophy and heart failure, and the findings may be
somewhat different in other models or in humans.
Conclusions. Chronic AT1R blockade with candesartan at
a subdepressor dose-attenuated concentric geometrical
changes accounting for subnormal end-systolic wall stress at
the compensatory stage but did not suppress compensatory
hypertrophy. However, excessive LV hypertrophy and in-
terstitial fibrosis were prevented in the advanced stage by
AT1R antagonist administration in association with atten-
uated activation of the ET pathway. These results demon-
strate that initial adaptive LV hypertrophy develops inde-
pendently from RAS activation and that RAS activation
and AT1R/ET system signaling are closely linked to the
transition to heart failure. Thus, the blockade of RAS by
AT1R blockade may be effective to inhibit the maladaptive
components of LV hypertrophy that contribute to the
development of failure.
Table 3. Effects of Candesartan and Enalapril on Geometry,
Hemodynamics and Pathology at 19 Weeks
Candesartan
(n 5 10)
Enalapril
(n 5 15)
Echocardiographic parameters
PWd (mm) 20.5 6 0.1 20.5 6 0.1 NS
LVDd (mm) 0.3 6 0.1 0.3 6 0.1 NS
FS (%) 21.4 6 1.6 21.0 6 1.5 NS
MFS (%) 20.3 6 0.6 0.5 6 0.8 NS
RWT (%) 216 6 2 216 6 2 NS
LVMI (mg/g) 21.2 6 0.3 21.2 6 0.1 NS
ESS (103 dynes/cm2) 22 6 7 17 6 7 NS
E/A 22.3 6 0.4 22.2 6 0.4 NS
Hemodynamic parameters
LV systolic pressure
(mm Hg)
22 6 9 35 6 7 NS
LVEDP (mm Hg) 212 6 1 28 6 2 NS
Tau (ms) 25 6 1 24 6 1 NS
Pathological parameters
LVMI (mg/g) 20.7 6 0.2 20.8 6 0.1 NS
Myocardial diameter (mm) 22.4 6 0.3 22.8 6 0.3 NS
Area of fibrosis (%) 24.0 6 0.5 25.5 6 0.2 p 5 0.0083
Pro-OH (mmol/g) 21.1 6 0.3 20.7 6 0.3 NS
Effects of ACE inhibitor were studied in the same model by the administration of
enalapril of 5 mg/kg/day from 8 to 19 weeks. The value was determined by subtracting
the untreated data from the treated data. Values are expressed as mean 6 SEM.
E/A ratio 5 the ratio of peak filling velocity at atrial contraction to peak early
diastolic filling velocity; ESS 5 end-systolic wall stress; FS 5 fractional shortening of
LV inner diameter; LV 5 left ventricular; LVDd 5 LV end-diastolic dimension;
LVEDP 5 LV end-diastolic pressure; LVMI 5 ratio of LV mass to body weight;
MFS 5 midwall fractional shortening of LV inner diameter; Pro-OH 5 hydroxypro-
line concentration; PWd 5 LV posterior wall thickness at end-diastole; RWT 5
relative wall thickness.
Figure 5. The mRNA levels of ppET-1, ECE, ET type A receptor and
ET type B receptor at 13 and 19 weeks. Each mRNA level was corrected
for an mRNA level of glyceraldehyde-3-phosphate-dehydrogenase and was
then normalized to a mean value of the age-matched control group,
respectively. *p , 0.05; **p , 0.01 versus control group; †p , 0.05; ††p ,
0.01 versus CAND(2) group. Values are means 6 SEM. ECE 5
endothelin-converting enzyme; ET 5 endothelin; ppET-1 5 prepro
endothelin-1.
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